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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
 
 Antivenom  serum is the most effective, if not the only effective,  
treatment  available  for management  of snake  bite  envenomation34.  
Adverse effects of the serum are  common23 and  anaphylaxis  can be 
fatal.  Increasing  the  safety  of  treatment  with antivenom  serum  for  
snake  bite  victims  is  therefore  a  matter  of high  priority. 
 
 Several  methods  have been  used to  reduce acute  adverse  
reactions  to the serum.  The  most  widely  used serum is  polyvalent but  
there is now  a trend  towards introduction of  monovalent  serum.  There  
is  no evidence  however  that this would  result in fewer adverse effects 
than  polyvalent  antivenom  serum.  Immunotherapy,  another  treatment  
option is  still at an  early  experimental  stage. A  small test  dose  of  
antivenom  serum  can be  used to  detect  patients  who may develop 
acute  adverse  reactions to antivenom.  This  method,  however is 
insensitive  and can give  rise  to anaphylaxis  by  itself34 57. 
 
 Prophylactic  use of  hydrocortisone and  antihistamines before 
infusion  with antivenom serum  is  also practised.  Antihistamines  
however  counter only the  effects of histamine release.  Hydrocortisone  
takes  time  to act,  and  hence it will not be  effective  against  acute  
adverse  reactions  that can develop  almost  immediately  after  serum  
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 treatment,  which is very  often  administered  urgently  to  snake  bite  
victims.  For  these  reasons,  it is not  an  established  practice  to give  
hydrocortisone or antihistamines routinely to  patients with  snake  bite  
before  antivenom serum  treatment. 
 
 Adrenaline is the   drug  of choice  in the treatment  of  
anaphylaxis,  and  it is likely to be  useful in the prevention of   such  
acute  reactions to serum.  There is  a  general  reluctance  to use 
adrenaline  because  of  potential side  effects  and lack  of  clear  
guidances  on use.  The  only  available  data on use  of adrenaline  before  
treatment with  antivenom  serum  are  from a few  uncontrolled  
retrospective  studies  from  Australia46.  These  data  suggest that  
adrenaline is  safe  and  effective  in reducing acute  adverse reactions36. 
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AIM OF THE STUDY 
 
 
 
 
 
 
 
 
  
AIM OF THE STUDY 
 
 To assess the efficiency and safety  of low dose  adrenaline  
injected  subcutaneously to prevent  acute  adverse  reactions to  
polyspecific  antivenom  serum in patients  admitted  to hospital  after  
snake  bite. 
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REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE 
 
 
EPIDEMIOLOGY  
Snake  bite is  a  major  public  health  hazard  in tropical  and sub-
tropical countries.   Patients with  snake envenomation present  as  
emergencies with significant  morbidity and mortality44. Although the 
exact  number of persons  inflicted by  snake bite is not known, it is 
estimated that about  2,00,000  persons are  annually bitten by snakes  in 
the country and about  15,000 of  these are fatal 13 48.  According  to a 
study  by  Sawai  in 1974,  71%  of the  victims are found in the  age 
group of  11-50 yrs and 75% of the victims were male1.  In  North India 
70-80% of bites are seen in the warmer  months May to October, while in 
a study  conducted  in Calicut  medical  college,  Kerala,  showed a 
maximum  incidence in winter months (Oct-Jan) with the incidence of 
complications also maximum during this period49.   The use of protective 
footwear, long trousers and lighting at night could reduce the incidence of 
snake bites.  Effective rodent  control would also  help43. 
 
VENOMOUS  SNAKES CLASSIFICATION 
3000 species of snakes in the world of which more than 200- 
ranging in size from 100mm long worm snakes to 6 metre long pythons - 
are  found in India.  These predators play a major role in the  maintenance 
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 of  the ecosystem39.   Approximately  1300 species  are  venomous.  
Venomous snakes  are  usually  defined  as those  which  possess venom  
glands and  specialized  venom - conducting  fangs,  which enable  them 
to inflict  serious  bites upon  their victims.   In general  there are  five  
families  of venomous  snakes  recognized:  the  Coloubridae,  which  
possess small rear  fangs; the  front-fanged  Elapidae  and  Hydrophidae;  
and the viper  group,  which  consists of the Viperidae  and Crotalidae.  
Venomous snakes  are  widespread  throughout the world.  However  they  
do not occur in several  islands,  New Zealand, Ireland, Iceland, the 
Azores  and Canaries. 
 
 In  South India the Irula tribals, over years,  have been supplying 
millions of snake  skins for export.  As this trade has been banned  today, 
they catch snakes for venom  extraction and this venom is then used in 
the process of antivenom production60. 
 
SYSTEMATIC  CLASSIFICATION OF VENOMOUS SNAKES IN 
THE WORLD 
 There are about 2500 to 3000 species of snakes of which about 500 
belong to five families of venomous snakes, Atractdaspididae,  Elapidae, 
Hydrophidae, Colubridae (some species) and Viperidae55. 
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 Family Species Distribution Characteristics 
Elapidae Kraits,  
Cobras,  
Mambas,  
Coral  snakes 
Americas,  Africa,  
Asia,  Australasia 
Small head,  short  and 
fixed  fangs. 
Viperidae   Viper  snakes Europe,  Africa,  
Asia 
Large,  flattened  
triangular head,   large  
grooved  fangs on the 
maxillary bone. 
Crotalidae   Rattlesnakes Americas,  Parts of 
Southeast Asia, 
Southeast Europe 
Similar to the family  
Viperidae,  but they   
possess heat-sensitive 
pits  on  the head 
Colubridae   Tree snakes In all  parts of the 
world, except  
Australasia 
Short  grooved  fangs 
at rear of  upper jaws. 
Hydrophidae Sea snakes Asia and  
Australasia 
Nostrils dorsally on 
head, flattened  tail.  
  
In India, the poisonous snakes belong to three broad  families: 
(a)  ELAPIDAE -  Cobras,  Kraits 
(b)  VIPERIDAE 
 (i) Viperinae - Russell's  Viper,  Saw-scaled Viper 
 (ii)  Crotalinae - Pit Viper 
(c) HYDROPHIDAE  - Sea Snakes 
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  The  King cobra is found in the forests or their vicinity in the  
Himalayas, Bengal, Assam and South India.  The Russell's viper is  
commonly   found in the plains of Punjab, Maharashtra, field of Andhra 
and Tamil Nadu  and the Brahmputra Valley. The pit viper is  found in 
the hilly  areas of Western Ghats and the Sunderbans in Bengal.  The  
banded krait is commonly  found  in  Assam, Bengal and  parts of South  
Asia.  Sand  viper is  found in  Rajasthan.  Kraits are usually  found in 
pairs 27. 
 
 If the physician has a mental picture of the four common poisonous  
snakes it would be  much easier for  him to know which bite has to be 
given   significance27.   
 
SNAKE VENOM 
 Snake venom is endowed with the most  complex  biochemical  
composition  of all known  poisons.   The  physical and  chemical  
qualities  of snake venom  vary  greatly not from  species to species, but 
amongst  different  varieties  of the same species and  even from time to 
time  in the same snake. 
 
 Snake  venom  contains a mixture  of powerful  enzymes  and non-
enzymatic  proteins   and polypeptidases.  They may be  in the form of 
enzymes like phospholipase,  RNA ase, DNA ase, hyaluronidase, 
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 acetylcholine esterase, collagenase, proteases, erepsin and sphie - 
oxidase, which enhance autolysis and putrefaction 28 33. 
 
The  important  venom constituent  effects  could be seen in variable  
combinations : 
 a)  PROCOAGULANT  ENZYMES (Viperidae predominantly) 
 b)  HEMORRHAGINS 
 c)  CYTOLYTIC/NECROTIC  TOXINS 
 d)  HAEMOLYTIC TOXINS 
 e)  MYOLYTIC  ENZYMES 
 f)  PRE  SYNAPTIC NEUROTOXINS (Elapidae  and  some  
viperidae) 
 g)  POST  SYNAPTIC  NEUROTOXINS (elapidae) 
 
 According to PJ Deoras the  average dry weight of lyophilised 
venom in one bite was 0.2g   from a Cobra, 0.15g from  a Russell's Viper, 
0.022g from a krait and 0.0046g from  an Echis. 3  28  29 
 
 A case  has been recorded where the bite of a  King cobra caused 
death in convulsions in three-quarters of an hour.  28 52. 
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 SYMPTOMS AND SIGNS OF SNAKE BITE 
EARLY  SYMPTOMS AND SIGNS 
 Following  the immediate  pain of the bite, there may be increasing  
local pain (burning,  bursting, throbbing)  at the site of the  bite, local 
swelling that gradually  extends  proximally  up the bitten limb and 
tender,  painful enlargement  of the regional  lymph  nodes  draining  the 
site of the  bite. However, bites  by  kraits,  sea snakes may be  virtually 
painless  and may cause negligible local  swelling.  Someone  who is 
sleeping may not even wake up  when bitten  by a krait  and there may be  
no detectable  fang  marks  or  signs of local  envenoming. 
 
LOCAL SYMPTOMS AND SIGNS  IN THE BITTEN PART 
 fang marks 
 local pain 
 local bleeding 
 bruising 
 lymphangitis 
 lymph node enlargement 
 inflammation (swelling,  redness, heat) 
 blistering 
 local  infection,  abscess formation 
 necrosis 
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 Local swelling is a valuable sign of viper bite to the extent that   its 
absence  excludes viper bite.  Local  swelling occurs  rarely with  the 
Asian Cobra bite,  but is  not seen with  Krait or sea snake bites2.   
 The bite marks are deeper in Vipers45.  
 
Generalised (systemic)  symptoms  and signs 
General 
 Nausea, vomiting,  malaise,  abdominal  pain,  weakness,  
drowsiness,  prostration  
 
Cardiovascular (Viperidae) 
 dizziness, faintness, collapse,  shock,  hypotension,  cardiac  
arrhythmias,  pulmonary  oedema, cardiac  arrest 
 
Bleeding and clotting  disorders (viperidae) 
 bleeding  from recent  wounds (including  fang marks, 
venepunctures etc)  and from  old partly-healed wounds. 
 spontaneous systemic bleeding - from gums, epistaxis,  bleeding 
into the tears,   haemoptysis,  haematemesis, rectal bleeding  or  
melaena, haematuria,  vaginal bleeding,  bleeding  into  the skin 
(petechiae,  purpura,  ecchymoses)  and  mucosae (e.g.  
conjunctivae), intracranial haemorrhage, meningism from  
subarachnoid haemorrhage,  lateralizing signs and/or  coma from  
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 cerebral haemorrhage.  Commonest haemorrhagic  manifestation  
seen in a study done by Virmani and Dutt in Jammu was  
haematuria  while for Reid it was haemoptyis.  53 37. 
Neurological (Elapidae,  Russels's  viper) 
 Drowsiness, paraesthesiae,  abnormalities of taste and smell,  
"heavy"  eyelids,  ptosis, external  ophthalmoplegia, 
paralysis of facial muscles,  difficulty  in opening mouth and 
showing  tongue  and  weakness of  other  muscles  
innervated  by  the cranial  nerves,   aphonia,  difficulty   in 
swallowing  secretions,  respiratory and generalized  flaccid  
paralysis. 
Skeletal muscle  breakdown (sea snakes,  Russell's  viper)   
 Generalised  pain,  stiffness and  tenderness of muscles,  
trismus,  myoglobinuria,  hyperkalemia,  cardiac  arrest,  
acute  renal  failure. 
Renal (Viperidae,  sea snakes)   

 Loin (lower back)  pain, haematuria,  haemoglobinuria,  
myoglobinuria,  oliguria/anuria, symptoms  and signs of 
uraemia  (acidotic  breathing,  nausea,  pleuritic  chest  pain 
etc). Ischemia (due to hypotension and DIC, nephrotoxic  
effect  of venom, pigment nephropathy associated with 
rhabdomyolysis  and intravascular  haemolysis contribute to 
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 the development of acute tubular necrosis, bilateral cortical 
necrosis and renal failure  commonly seen with Russell's 
viper. 56 
 V.S.Tembe et al on autopsy found haemorrhagic interstitial nephritis,  
toxic proliferative glomerulitis intracerebral haemorrhage and necrosis of 
the liver 21 28. 
Endocrine (acute  pituitary / adrenal  insufficiency)  (Russell's  viper) 
 Acute phase :  shock,  hypoglycaemia  
 Chronic phase  (months  to years after the bite) :  weakness,  loss of  
secondary sexual  hair,  amenorrhoea, testicular  atrophy,  
hypothyroidis,  hypopituitarism etc. 
 
LONG TERM COMPLICATIONS (SEQUELAE)  OF SNAKE  BITE 
 At the site of the bite,  loss  of  tissue  may result  from sloughing 
or surgical   debridement of necrotic  areas  or  amputation :  chronic 
ulceration, infection, osteomyelitis or  arthritis may  persist  causing  
severe  physical  disability.  Malignant   transformation  may occur in  
skin ulcers  after a number  of years. 
 
Chronic  renal failure   occurs after  bilateral cortical  necrosis 
(Russell's  viper bites)  and chronic  panhypopituitarism or  diabetes  
insipidus after  Russell's  viper bites in Myanmar and South India.  
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 Chronic  neurological deficit  is seen in the few patients  who survive  
intracranial haemorrhages  (Viperidae). 
 
 R.Ray and K. Bhattacharya report the  case of a  male, aged 45, 
who was bitten by  a viper on his  right foot.  Inspite of 80cc of  
polyvalent  antivenin serum, he developed oliguria, haemetemesis and 
was delirious and semi concious  from the eighth to the tenth day.  He had 
absolute   anuria with raised blood urea,  and was given  a large amount 
of intravenous glucose.  Later on,  he  recovered completely 19    28. 
 
 Bites  by cobras, king cobras,  kraits or sea  snakes may lead,  on 
rare occasions,  to the rapid  development  of  life-threatening  respiratory  
paralysis.  This  paralysis might be  delayed by  slowing down the  
absorption of  venom from the  site of the bite.  The  following technique  
is  currently  recommended. 
 
PRESSURE  IMMOBILIZATION METHOD.  
 Pressure  immobilization  is  recommended  for  bites by  
neurotoxic  elapid snakes, including sea snakes,  but should not be used 
for  viper bites  because  of the danger of   increasing the local  effects of 
the necrotic venom. 
 
 In a  human volunteer study  simulating intradermal  and 
subcutaneous envenomation,  using  labeled  radiotracer,  immediately 
13 
 wrapping an  entire extremity with a  rolled  elastic  bandage to a pressure  
of 50-70 mm Hg  significantly  delayed transit time from  periphery  to 
the systemic  circulation  12 18.  The wrapping  procedure,   (the Sutherland  
Wrap) is intended to collapse lymphatics and superficial veins to retard 
venom  uptake12.   
 
 The pressure  immobilization technique has been used for 
treatment of  non necrotizing elapid snake bites in Australia  where  
systemic  toxicity  is the major  concern  and transit  times can be  
prolonged58.  
 
SPECIES DIAGNOSIS 
 If the dead  snake has  been brought,  it can be  identified.   
Otherwise,  the species  responsible  can be  inferred  indirectly  from  the 
patient's   description  of the snake  and the clinical  syndrome  of 
symptoms  and signs.  This will be  important  when operating  under  
various  international  peace  keeping  missions  where  monospecific  
antivenoms are  available. 
 
INVESTIGATIONS / LABORATORY TESTS 
20 minute  whole   blood  clotting  test (20  WBCT) 
 This very  useful and informative  bedside  test  requires very little  
skill and  only one piece  of  apparatus  - a  new, clean,  dry, glass  vessel 
(tube or  bottle) 
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 OTHER TESTS 
i. Haemoglobin  concentration / haematrocrit :  a  transient increase  
indicates  haemoconcentration  resulting  from a generalized  
increased in capillary  permeability  (e.g.  in Russell's  viper bite).  
More  often,  there is a decrease  reflecting   blood loss or,  in the 
case  of Indian and  Sri Lankan  Russell's  viper  bite,  
intravascular haemolysis. 
ii. Platelet  count :  this may be  decreased  in victims  of viper bites. 
iii. White blood  cell  count:  an early  neutrophil  leucocytosis  is  
evidence of  systemic  envenoming  from any species. 
iv. Blood film :   fragmented  red cell ("helmet  cell",  schistocytes)  
are  seen when there  is  microangiopathic  haemolysis. 
v. Plasma / serum may be  pinkish  or  brownish  if  there is gross 
haemoglobinaemia  or  myoglobinaemia. 
vi. Biochemical  abnormalities :  aminotransferases  and muscle  
enzymes  (creatine  kinase,  aldolase  etc)  will be  elevated  if 
there is severe local  damage  or,  particularly,   if there is 
generalized  muscle  damage  (Sri Lankan  and South  Indian 
Russell's  viper  bites,  sea  snake bites).  Mild  hepatic 
dysfunction is  reflected  in slight  increases in other  serum  
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 enzymes.  Bilirubin is elevated  following  massive  extravasation 
of blood.  Creatinine, urea  or  blood  urea  nitrogen  levels  are  
raised  in the renal  failure  of Russell's  viper and  saw-scaled   
viper  bites  and  sea  snake   bites.  Bicarbonate  will be  low in  
metabolic  acidosis (e.g.  renal  failure). 
vii. Arterial blood  gases and pH may show   evidence  of respiratory 
failure (neurotoxic  envenoming)  and acidaemia (respiratory or  
metabolic  acidosis).  
viii. Desaturation :  arterial oxygen  desaturation can be  assessed  
non-invasively  in patients  with  respiratory   failure  or shock 
using  a  finger  oximeter. 
ix. Urine  examination :  the  urine  should  be tested  by  dipsticks  
for  blood/haemoglobin/myoglobin.  Standard   dipsticks do not 
distinguish   blood,   haemoglobin and myoglobin.  Haemoglobin  
and  myoglobin can be  separated  by  immunoassays but there  is 
no easy or  reliable  test.  Microscopy  will confirm  whether  
there are  erythrocytes  in the  urine.   Red  cell  casts  indicate  
glomerular  bleeding.  Massive  proteinuria is an  early  sign  of 
the generalized  increase  in capillary  permeability  in Russell's  
viper  envenoming. 
16 
 IMMUNODIAGNOSIS  
 Enzyme linked immunosorbent assay is a very important  tool for  
studying  both the epidemiological  and clinical  effects of snake bite in  
humans.  In places where  specific  antidote  venom is available  against 
each species, if the  snake is not brought   along with the victim  for  
identification,  immunodetection of  specific  snake  venom antigen in 
body  fluids of  the patient will help in management56.   
 It has been proved by ELISA that effects of  envenomation depend 
upon venom hours (i.e., blood venom level  x  time elapsed  between bite 
and institution of treatment)  rather than  blood level of venom17. 
 ELISA  by detection of snake venom antibody can be  used for 
retrospective  diagnosis of  envenoming in epidemiological studies38. 
 
ANTIVENOM  TREATMENT 
Antivenom is the only specific antidote to  snake  venom. 
A most important   decision  in the management  of a snake bite  
victim  is  whether  or  not to give antivenom. 
 
 Antivenom is immunoglobulin (usually  the enzyme  refined F (ab) 
2 fragment   of  IgG) purified  from the  serum or  plasma  of  horse  or 
sheep that has been  immunized  with the   venoms  of  one or more 
17 
 species  of  snake.  "Specific"  antivenom, implies  that the  antivenom 
has been raised  against   the venom of the snake  that has bitten  the 
patient and that it can therefore   be expected  to contain specific  
antibody  that will  neutralize  that particular  venom.  Monovalent or  
monospecific  antivenom  neutralizes  the venom  of only  one  species of 
snake.  Polyvalent  antivenom  neutralizes  the venoms  of  several  
different  species  of snakes.  For  example,  Haffkine, Kasauli, Serum  
Institute  of India and Bengal "polyvalent  anti-snake venom serum"  is  
raised  in  horses  using  the venoms of the four  most  important 
venomous  snakes  in India  (Indian cobra,  Naja  naja;  Indian krait,  
Bungarus  caeruleus;  Russell's   viper,  Daboia  russelii;  saw-scaled  
viper,  Echis  carinatus).  1 ml  of  polyvalent  ASV  in India  neutralizes  
0.6 mg  of  Cobra  and  Russell  Viper  venom and  0.45  mg of Krait and 
Saw  scaled  Viper  venom.  Antibodies  raised  against  the venom  of 
one species  may have  cross-neutralising   activity  against  other  
venoms,   usually  from closely  related  species.   This  is known  as  
paraspecific  activity.  For  example,  the manufacturers  of  Haffkine  
polyvalent  anti-snake  venom   serum  claim that this antivenom also 
neutralizes  venoms of two  Trimeresurus species (Pit  vipers). Details  of  
Indian  manufacturers  of  ASV  are  attached  as  appx. 
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MANUFACTURERS  OF  ASV  IN INDIA 
 
1.   Haffkine  Bio  Pharmaceutical  Corporation Ltd. 
 Acharya Donde  Marg,, Panel, Mumbai - 400 012 
 Tele :  022-4129320 
 FAX  :  022-4147564 
 
2. Central  Research  Institute (Shimla Hills) 
 Kasauli, Himachal Pradesh - 173 204 
 Tele :  0179-32060 
 FAX  :  0179-272049 
 
3. Serum Institute of  India Ltd 
 212/2  Hadapson, Pune - 411 029 
 Tele :  020-672016 
 FAX  :  020-672040 
 
4. Kings  Institute of  Preventive  Medicine 
 Guindy,  Chennai. 
 
5. Bengal  Chemical and Pharmaceuticals 
 6, Ganesh Chunder Avenue, 
 Kolkata 
 Tele :  033-2257697 
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 MANAGEMENT 
 There are no universally accepted  standards  of care for many  
aspects of treatment59.  
 
INDICATION FOR ANTIVENOM 
Antivenom treatment is recommended if and when a patient with  proven 
or  suspected snake   bite  develops one or more  of the following signs. 
 
Systemic  envenoming 
• Haemostatic  abnormalities  :  spontaneous systemic bleeding, 
coagulopathy  or  thrombocytopenia    
• Neurotoxic signs :  (clinical) 
• Cardiovascular abnormalities (clinical),  abnormal ECG 
• Acute renal failure :  oliguria/anuria (clinical),  rising blood  
creatinine/urea  (laboratory) 
• (Haemoglobin-/myoglobin-uria:) dark brown urine (clinical)  
urine dipsticks, other evidence of  intravascular  haemolysis or 
generalized  rhabdomyolysis (muscle aches and  pains,  
hyperkalemia) (clinical, laboratory) 
• Supporting  laboratory  evidence  of systemic  envenoming 
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 Local  envenoming 
• Local swelling  involving more than half of the bitten limb (in the 
absence  of a tourniquet) 
• Swelling  after bites on  the digits (toes  and especially  fingers) 
• Rapid  extension of swelling  (for example  beyond the wrist or 
ankle within a few  hours  of  bites on the hand  or feet) 
• Development  of an enlarged tender lymph  node  draining  the 
bitten limb. 
 
PREDICTION OF ANTIVENOM  REACTION 
Skin and  conjunctival  "hypersensitivity"  tests may  reveal IgE  
mediated  Type  I  hypersensitivity  to horse or  sheep  proteins  but  do 
not predict  the large  majority of  early  (anaphylactic)  or  late  (serum  
sickness  type)  antivenom  reactions.  Since  they  may  delay  treatment  
and can in themselves  be  sensitizing,  these  tests  should not be  used. 
 
CONTRAINDICATIONS  TO  ANTIVENOM 
There  is no absolute  contraindication  to  antivenom  treatment,  
but  patients  who  have  reacted  to horse  (equine)  or  sheep  (ovine)  
serum  in the past  (for  example  after  treatment  with equine  antitetanus 
serum,     equine  or ovine antivenom)  and  those  with  a strong  history  
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 of  atopic  diseases  (especially  severe asthma)  should be  given  
antivenom only  if  they have  signs of  systemic  envenoming. 
 
PREVENTION  OF ANTIVENOM REACTIONS  
Recent  studies have  indicated  that,  while  intramuscular 
promethazine is ineffective, subcutaneous epinephrine (adrenaline)  
(0.1%  solution,  adult  dose  0.25 mg  given  immediately   before  the 
start of  antivenom  treatment)  reduces  the incidence  of early  
antivenom  reactions34.  In  asthmatic  patients, prophylactic  use  of  an 
inhaled  adrenergic B2  agonist such  as  salbutamol may  prevent  
bronchospasm.   
 
 
In a  study, the cutaneous and systemic signs and  symptoms of  
immediate  hypersensitivity  were all effectively  treated  with 
antihistamines and  epinephrine, with no adverse  sequelae 12  22.   In life  
threatening situations  and if the Fab antivenom is not available,  
administration of antivenom  to patients  with a positive skin test or 
known  allergy to  horse serum is  warranted 12 26 32. 
 
ADMINISTRATION  OF ANTIVENOM 
 Epinephrine (adrenaline) should always be drawn up in readiness 
before  antivenom is administered. 
22 
  Antivenom should be given by  the intravenous  route whenever 
possible. 
 Freeze-dried (lyophilised)  antivenoms are  reconstituted, usually  
with 10 ml of  sterile  water for  injection  per ampoule.  The  freeze-dried 
protein  may be  difficult  to dissolve.  Two  methods  of  administration  
are  recommended : 
 
1.  Intravenous infusion : reconstituted freeze-dried or  neat  liquid  
antivenom is  diluted in  approximately  5-10ml  of isotonic  fluid per kg   
body  weight  (i.g.  250-500 ml of isotonic saline  or  5% dextrose in the 
case of an adult  patient)  and is infused  at a constant  rate  over a  period 
of  about one hour.  This method  has the advantage that intravenous  
access is  available for the emergency  treatment  of reaction. 
 
2.  Intravenous  "push"  injection :  reconstituted  freeze-dried  
antivenom  or  neat  liquid  antivenom  is given by  slow intravenous  
injection (not  more than 2 ml/minute).   It is economical, saving  the use 
of  intravenous  fluid,  giving sets,  cannulae  etc.  It  has been  found 
there is no  difference in  reaction  between the two methods35.  
Patients  must  be  closely  observed  for at least  one hour after  starting  
intravenous  antivenom administration,  so that early  anaphylactic  
antivenom reactions can be  detected  and treated  early  with  epinephrine 
(adrenaline). 
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 DOSE OF ANTIVENOM 
 Snakes inject the same dose of venom into children and  adults.  
Children must  therefore be given exactly  the same dose of antivenom as 
adults. 
 
Viper  bites 
The  initial dose of ASV  for  Viper  bites  depends on clinical  
manifestations of  envenomation 
 (a)  Progressive  local swelling  - 50 ml 
 (b)  Mild   systemic   envenomation  or  mild  coagulagram  
abnormalities --  100 ml 
(c) Severe poisoning, rapidly  progressive  or overt  hemolysis or  
coagulopathy - 150  - 200 ml 
 
Elapid bites 
Higher   doses are indicated in elapid bites since  the elapid venom 
is less antigenic and its absorption is faster.  For  patients presenting with 
neurotoxic features  initial  dose of ASV given is 100 ml36.  The  dose  for 
children  is the same as that for adults.  The dose should  be repeated after  
6 hours  if clotting  parameters  are deranged.  If  there are signs  of  
severe  neurotoxicity  the dose may be repeated  more  frequently  (even 
as  early as  30 minutes)  till a  satisfactory  response  is  obtained. 
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 NEWER ANTIVENINS 
 A new antivenin (Crofab)  has replaced the Wyeth horse serum 
based product.  With local signs   such as swelling, pain  and ecchymoses 
but  no systemic  symptoms, give 4-6 vials  of crotalid antivenin (Crofab) 
by slow intravenous drip in  250-500ml Saline.  Repeated  doses of  2 
vials every 6 hours for upto 18 hours  has been recommended.  For  
elapid envenomation, give 1-2 vials of specific antivenin as soon as 
possible  11 25 31. 
 
 Thus  if dose has been adequate, clotting time should be  normal by 
6 hrs  9  55. 
 
 There  is a controversy  about how long  after  envenomation 
Antivenom therapy is  still effective.  Carrison et al claim that it is most 
useful if given within 4 hrs, less if delayed for 8 hrs and doubtful  if 
delayed after  24 hrs41. 
 
 However  Dwivedi et al have reported  therapy  with Antisnake  
venom to be beneficial even after  8 days and state that these is  no fixed 
time limit10. 
 
 After  two preclinical trails  studied, crotalidae  polyvalent immune 
Fab (ovine), the therapeutic  regimen  was empirically determined  to 
include repeat  doses of  4-6 vials until "control"  is obtained,   followed 
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 by  regularly  scheduled maintenance   infusions.  The  manufacturer  
defines   control as arrest of  local tissue  manifestations  and  return of 
coagulation parameters,  platelet counts and  systemic signs to normal.  
However  select patients  develop coagulopathy and thrombocytopenia  
that is resistant to  antivenom treatment  12 40.   Some authors  advocate  
control to mean clear   improvement  in  haematologic  parameters  rather  
than complete  normalization  12 40. 
 
 The use of a systemic severity of illness  scale has  demonstrated 
that  antivenom will correct  coagulopathies and  thrombocytopaenia  
associated  with  envenomation from  snakes  native  to  the united     
states  7   12.   
 
 Recurrent neurotoxic envenoming after  treatment of cobra bite  
has also  been  described. 
 
CRITERIA  FOR  REPEATING  THE INITIAL   DOSE  OF  
ANTIVENOM 
Criteria  for giving more  antivenom 
* Persistence or  recurrence  of  blood   incoagulability  after  6 hr. 
*  Deteriorating   neurotoxic  or  cardiovascular  signs after  1-2 hr 
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  Studies have shown that clotting  abnormalities may reappear  upto 
72 hours after  their apparent  complete  nomalization.  This  is attributed  
to  delayed   venom  absorption  from site of bite 11.   
 
 If the  blood remains incoagulable  six hours  after  the initial dose 
of antivenom,  the same  dose should be  repeated.    This is  based on the 
observation that, if a large  dose  of  antivenom  (more  than enough to 
neutralise the venom procoagulant enzymes)  is given initially, the time  
taken for the liver to  restore coagulable  levels of fibrinogen and  other  
clotting  factors  is  3-9 (mean 6) hours. 
 
 In patients  who continue to bleed  briskly, the dose of antivenom 
should be  repeated  within  1-2 hours. 
 
 In case of deteriorating  neurotoxicity or  cardiovascular  signs, the 
initial dose of antivenom should be  repeated  after  1-2 hours,  and full  
supportive  treatment must be  considered. 
 
ANTIVENOM  REACTIONS 
 A proportion  of patients,  usually  more than 20%  develop  a  
reaction either early  (within a few hours)  or late  (5 days  or more)  after 
being  given antivenom. 
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  Incidence of anaphylactic / oid reaction -23.56%  for  polyvalent  
antivenin (crotalidae),  14%  for  Crofab.  Incidence  of  delayed  serum 
sickness - 18-86%  for the former and 16%  for the latter30.  There are  
three types  of  anaphylactoid   reactions-early   anaphylactoid,  pyrogenic  
and late30. 
 
EARLY  ANAPHYLACTIC  REACTIONS 
 Usually  within 10-180  minutes of  starting  antivenom, the  
patient  begins to  itch (often  over the scalp) and develops  urticaria, dry 
cough, fever,  nausea,  vomiting,  abdominal  colic,  diarrhea  and  
tachycardia.  A  minority  of these patients  may develop  severe life-
threatening anaphylaxis : hypotension,  bronchospasm and angio-oedema.  
Fatal reactions have probably  been  under-reported  as  death  after snake  
bite is usually  attributed  to the venom. 
 
 In most  cases, these  reactions are not truly "allergic".  They  are 
not IgE-mediated type  I hypersensitivity  reactions  to horse  or  sheep 
proteins as there is no evidence  of  specific  IgE,  either  by skin  testing 
or  radioallergosorbent  tests (RAST). Complement activation by  IgG  
aggregates or  residual  Fc  fragments  or  direct  stimulation  of mast  
cells  or  basophils by antivenom  protein are more  likely mechanisms for  
these  reactions. 
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 PYROGENIC (ENDOTOXIN)  REACTIONS  
 Usually  develop  1-2 hours  after treatment.  Symptoms  include  
shaking  chills (rigors),  fever,  vasodilatation and a fall in blood pressure.  
Febrile  convulsions  may be  precipitated   in  children.  These  reactions  
are  caused  by  pyrogen contamination during the manufacturing  
process. They  are  commonly  reported. 
 
LATE (SERUM SICKNESS TYPE)  REACTION :   
 Develop 1-12 (mean 7) days after  treatment .  Clinical  features  
include   fever,  nausea,  vomiting,  diarrhoea,  itching,  recurrent  
urticaria,  arthralgia,  myalgia,  lymphadenopathy,  periarticular  
swellings,  mononeuritis  multiplex,  proteinuria with  immune  complex  
nephritis and rarely  encephalopathy.   Patients who suffer  early  
reactions  and  are  tested  with  adrenaline,  antihistamines  and  
corticosteroids  are  less likely to develop  late reactions. 
 
TREATMENT  OF  EARLY  ANAPHYLACTIC  AND  
PYROGENIC  ANTIVENOM  REACTIONS 
At the earliest  sign of a reaction 
 Antivenom  administration  must be  temporarily  suspended. 
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  Epinephrine  (adrenaline)  (0.1%  solution,  1 in  1000,  1 mg/ml)  
is the effective  treatment  for  early  anaphylactic  and  pyrogenic  
antivenom  reactions. 
 
 Epinephrine  (adrenaline)  is given  subcutaneously  if  mild in an  
initial dose of  0.5 mg  for  adults,  0.01 mg/kg body weight  for children.  
Severe,  life  threatening  anaphylaxis  can  evolve very  rapidly  and so 
epinephrine  (adrenaline) should be  given  intravenously  at the very  first 
sign of a severe  reaction,  even when only  a few spots of  urticaria have  
appeared or at the start  of  itching,  tachycardia  or  restlessness.  The  
dose  can be  repeated  every  5-10 minutes if the patient's  condition is  
deteriorating. 
 
ADDITIONAL TREATMENT 
 After  epinephrine (adrenaline),  an  anti-H1  antihistamine  such as  
chloropheniramine  maleate (adults 10 mg,  children 0.2 mg/kg  
intravenous  injection  over  a few minutes)   should be given  followed 
by  intravenous  hydrocortisone (adults  100 mg,  children 2 mg/kg  body 
weight).  H  2 blockers may also be used  but after  H1  blockade.  The  
corticosteroid is  unlikely to act  for  several  hours,  but  may prevent  
recurrent   anaphylaxis. 
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  In  pyrogenic  reactions  the patient  must also be  cooled  
physically  and with antipyretics (for example  paracetamol by mouth or  
suppository).   Intravenous  fluids  should be  given  to correct  
hypovolaemia. 
 
SUPPORTIVE  TREATMENT 
 Tetanus  prophylaxis 
 Antibiotics 
 Surgical  debridement of dead tissue/amputation 
 Fasciotomy for  intracompartment  syndromes. 
 Patients  with respiratory  paralysis  should be given  IV  
neostigmine  0.5 mg  slow IV  with  IV  atropine  0.6 mg  1/2 hrly   for  5  
doses and repeated  thereafter   at  increasing  intervals if required.  
Endotracheal  intubation  and  artificial  ventilation may be  needed. 
 Steroids are  advocated in  both patients  presenting   with bleeding  
tendencies and with  neurological  manifestations.  (Hydrocortisone 50 to 
100 mg 1. V  8th  hrly)  However  its use  remain controversial 14.  
 
 Treatment of  DIC :  In a situation  of viper  bite  the 
manifestations  of  primary  fibrinolysis  and DIC  are  reversible  by  
administration of  ASV.  However,  if  a person  has severe  bleeding  
manifestations  despite  ASV  administration,  fresh  frozen  plasma,  
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 cryoprecipitate  and platelet  concentrates  can be  given.  If  these  blood  
constituents  are  not available   fresh  blood can be  transfused.    
  
 Some studies show that  if heparin 10,000 units  is given  
intravenously stat followed by  5000 units  8th hrly IV and  continued for 
48 hrs,  it is useful in  the prevention  of  DIC.  Yet other studies   have 
shown  it to be  ineffective   and  worsening   bleeding42. 
 
Conservative  treatment  when no antivenom is available 
 This will be  the situation  in many  parts of the regions,  where  
supplies  of  antivenom  run out  or  where the bite is known  to have been  
inflicted  by  a species against  whose  venom  there is no  available  
specific  antivenom : for  example  for  bites  by the Malayan krait 
(Bungarus candidus),  coral snakes (genera  Calliophis  and Maticora),  
sea snakes,  the mangrove/shore pit viper (T purpureomaculatus) and the 
mountain pit  viper (Ovophis  monticola). 
 
RECENT  ADVANCES 
 (a)  purification  of  IgG  by  immunosorbent  affinity  
chromatography  have  yielded  purified  polyvalent  antibodies with high 
affinity for  crotalid  venom.  This  belongs to a subclass of  equine  IgG  
called  IgG (T) 
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 (b) F (ab)  fragments  of IgG using  papain digestion are also being  
studied.  These  retain the affinity  for the venom  of the large  IgG  
molecules.  They  also  enhance the renal  clearance of the  venom 
molecules and are less immunogenic than the whole antibody. 
 
 (c)  Antisnake  vaccines are also under trial at the Tropical School 
of  Medicine,  Kolkata.  These  newer  treatment  modalities are  still in 
the experimental  stages and need to be developed  further  before use  in 
clinical practice. 
 
 SNAKE BITE :  CAUSES OF HYPOTENSION AND SHOCK 
 Anaphylaxis 
 Vasodilatation 
 Cardiotoxicity 
 Hypovolaemia 
 Antivenom reaction 
 Respiratory failure 
 Acute  pituitary and adrenal insufficiency 
 Septicaemia 
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 EPINEPHRINE 
 
 Epinephrine (adrenaline) is a  potent stimulant  of both    α and  β  
adrenergic receptors and its effects on target organs are thus complex20. 
The peripheral actions of adrenaline in most tissues has been clearly 
differentiated  into those mediated by α or  β    receptors  depending  on 
the  predominant receptor type  present in a  given  tissue. 
 Adr - α1 + α2 + β1 + β2 and weak β3  action 51 
 
Administration and Preparation : 
 Adrenaline (epinephrine) 0.2 - 0.5 mg S.C, 1.M, .5% by aerosol ; 
action lasts 1/2 to 2 hrs51. 
 
ADVERSE  EFFECTS AND CONTRAINDICATIONS : 
1.  Transient restlessness, palpitation, anxiety,  tremor, pallor  may occur 
after  s. c / i.m  injection of adrenaline. 
2.  Marked rise in BP  leading to  cerebral  haemorrhage, ventricular  
tachycardia / fibrillation are the hazards of large  doses of  inadvertant  IV 
injection. 
3.  Adrenaline is  contraindicated in hypertension, hyperthyroidism and 
angina pectoris. 
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  It should not be given during anaesthesia with halothane (risk of  
arrhythmia) and to patients receiving  β blockers,  marked rise in BP  can 
occur51 . 
Use of  epinephrine 
 Anaphylaxis 
 glaucoma 
 Asthma & to cause vasoconstriction 5 
 
HYPER SENSITIVITY  REACTIONS  
 Hyper sensitivity  reactions have been  classified  traditionally  in  
to immediate and  delayed types,  based on the time required  for a 
sensitized host to develop  clinical reactions on  re exposure to  the  
antigen.  Anaphylaxis  comes  under  immediate  hypersensitivity.  (B cell 
or antibody mediated)  4.   The biologically  active  molecules that are 
responsible  for the manifestations  of  Type I  hypersensitivity are  stored 
within mast cells and basophil  granules and are  synthesized after  cell 
triggering.  The  signal for  the release  or  production of these  molecules 
is  the cross linking of  surface  bound IgE  by antigen 8. 
35 
                                                         
 
 
6
36 
  
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
DESIGN   
 Prospective, single  blind,  randomised, placebo  controlled  trial. 
 
SETTING   
 Thanjavur  Medical College Hospital  during the period  of July 
2007 to September  2007. (Rice paddy  harvesting   season,   when there 
is a high admission  rate  for  snake bite).  188 pts  were  admitted during 
this period.  88 of them were  excluded  according to the  exclusion  
criteria.  
 
SUBJECTS  
 Hundred  patients  with signs  of  envenomation after  snake  bite  
randomized  to receive  either  adrenaline (study group)  or placebo 
(controls)  immediately  before infusion of  antivenom serum. 
 
INTERVENTIONS  
Adrenaline  0.25 ml (1 : 1000) 
 
MAIN OUTCOME  MEASURES  
 Development  of acute  adverse  reactions to  serum  and  side 
effects  attributable  to  adrenaline. 
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 METHODS  
 Consecutive  patients  not having  exclusion  criteria  who were  
admitted  after  a snake bite  and  required   antivenom  serum  because of  
systemic envenomation   received  either  adrenaline  (study group)  or  
identical  appearing  placebo  (controls)  as  pretreatment. 
 
 Patients  were  excluded  from the study   if  they were  pregnant, 
aged  under  12 or over  70 years,   said  they   had  received  antisera,  
including  antivenom  serum,  in the past;   had  known adverse  reactions 
to  adrenaline,   atopy,  wheezing,   hypertension,  ischaemic  heart  
disease,   transient  ischaemic  attacks,  strokes  or unexplained  focal  
neurological   signs or  had  received  any treatment  other than  first aid  
before   admission.  Patients  were also  excluded  if  electrocardiography 
on  admission  showed  ischaemic  changes  or  arrhythmias.  Written  
informed  consent  was  obtained  from all participating  patients. 
 
TREATMENT  AND FOLLOW UP  
 All patients  were  given  0.25 ml   of  1:1000 adrenaline or  
placebo  injected  subcutaneously  in to  the forearm   immediately  
before  infusion  with  antivenom.   Placebo  consisted  of  0.9%  sodium  
chloride.  Adrenaline and placebo were  drawn   into 1 ml "insulin"   
syringes  which were stored  in closed  rigiform  containers  and  
refrigerated  at  40C.   No test doses of  antivenom was used and neither   
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 hydrocortisone  nor  promethazine were given as  pretreatment.  Patients 
were  monitored for   development  of acute  adverse reactions  to the 
serum  and the test drug.  Pulse and  Blood pressure  (every 15  minutes)  
and  an electrocardiogram  (at  least once  within 30 minutes  of being 
given  the test  drug and whenever  clinically   indicated)  were  
monitored  during  infusion of  antivenom and for one hour thereafter. 
 
 Neurological  evaluations   were done at the beginning  and  end of 
the infusion and whenever  relevant  during   the observation  period.  
Patients  who received  antivenom serum were  kept in hospital  for 
atleast  96 hours after the infusion. 
 
 Acute  adverse  reactions   were  graded  as mild,   moderate  or  
severe  according  to the following  Criteria. 
 
Mild   -   pruritis,  skin  rash, without  pruritis,  mild  urticaria,  fever,   
rigors,  nausea, vomiting. 
 
Moderate- extensive  urticaria,  facial oedema,  bronchospasm  without  
cyanosis. 
 
Severe- Pulmonary oedema,  bronchospasm with  cyanosis,  stridor,  
shock  or  a reaction  developed  while  the patient   was  receiving the  
serum or if the patient developed  arrhythmias,  ischaemic   changes in 
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 the electrocardiogram or a measurable  rise in blood  pressure  (systolic -
>20 mm Hg or Diastolic  > 10 mm Hg  from level  before  test  drug was 
given)  after the  test  drug  and the serum,  he  or she was given 
appropriate  treatment  and did not  take  further  part in the trial. 
 
 Reactions to antivenom serum  were  initially  treated by  stopping 
the  infusion and  administering   0.5ml  of  1 : 1000  adrenaline  
intramuscularly,  200 mg  hydrocortisone intravenously  and 25 mg  
promethazine  intramuscularly. 
 
Statistical Analysis 
Analysis  was done using  Chi square  test and p value  assessed.   
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 DESIGN OF  RANDOMIZED  CONTROLLED  TRIAL 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NO OF  PATIENTS IN WHOM  
ANTIVENOM SERUM WAS 
INDICATED 
n = 188 
 
Included  in the study 
n = 100 
 
Not included in the study or 
Excluded  from the study 
n = 88 
REASONS 
TREATMENT STARTED  IN  
PERIPHERAL HOSPITAL,  
AGE >70 YEARS 
ATOPY 
WHEEZING, 
HYPERTENSION, 
IHD, 
TOO ILL  TO  GET  CONSENT 
No receiving 
adrenaline  as   
pre-treatment  
n=50 
no  receiving  
placebo  
as pre treatment 
n = 50 
ACUTE ADVERSE 
REACTIONS  TO  
ANTIVENOM  SERUM 
n=5 
ACUTE  ADVERSE 
REACTIONS TO 
ANTIVENOM  SERUM 
n =24 
Randomization 
Study group 
n=50 
Control group 
n=50 
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 GENERAL  FEATURES 
 The study  started in July 2007  and ended in September 2007  
when   hundred  patients had been recruited. 
 
 Within this three month period  out of a total of  one hundred and 
eighty eight patients  admitted  in Thanjavur Medical College  Hospital 
with envenomation after  snake  bite for whom  treatment   with 
antivenom  serum was  indicated,  only  hundred  could be  recruited to 
the study  as the others  had one or more exclusion  criteria.  Of  the 
hundred  patients recruited fifty received  adrenaline and  fifty received  
placebo.  (Ten Vials)  Haffkine  Polyspecific  antivenom  serum 
(Haffkine  Laboratories,   Mumbai,  India)  an  equine serum  product  
were used for all patients.  The  serum was administered   intravenously 
as a  200 ml  infusion  at fifty  drops per  minute  over one hour.  All 
serum used during  the study was from the same batch  supplied  to the 
hospital. 
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 CHARACTERISTICS AND DEGREE OF ENVENOMATION ON 
ADMISSION OF PATIENTS  ACCORDING TO ALLOCATION 
TO PRE TREATMENT  WITH ADRENALINE OR PLACEBO IN 
A NUTSHELL (values  are  numbers  of patients  unless stated 
otherwise) 
 
DETAIL ADRENALINE 
(n=50) 
PLACEBO 
(n=50) 
MALE 32 30 
MEAN (SD ; RANGE) AGE 
(YEARS) 
40.19 (13.07;19-65) 41.77 
 (11.6;17-65) 
MEAN (SD;RANGE) WEIGHT 
(KG) 
58.22 (4.94; 48-66) 58.17  
(5.04;50-70) 
SPECIES OF SNAKE *   
UNCERTAIN 22 31 
RUSSELLS VIPER 18 13 
COBRA 3 3 
KRAIT 7 3 
SYSTEMIC ENVENOMATION 48 46 
COAGULOPATHY 22 30 
NEUROMUSCULAR 
COMPLICATIONS 
16 10 
RENAL IMPAIRMENT 5 3 
MORETHAN ONE FEATURE OF  
ENVENOMATION 
5 3 
COAGULOPATHY & RENAL 5 3 
NEUROMUSCULAR & RENAL - - 
COAGULOPATHY, 
NEUROMUSCULAR & RENAL 
- - 
SIGNIFICANT LOCAL 
ENVENOMATION ONLY 
6 5 
SEVERE LOCAL SWELLING(#) 26 34 
 
#  Swelling  of more than half of bitten limb.  (none  had necrosis) 
*  species of snake mentioned only when dead  snake brought to hospital. 
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 ACUTE  ADVERSE  REACTIONS TO  ANTIVENOM SERUM TO  
PATIENTS  BITTEN BY  SNAKES, ACCORDING TO PRE 
TREATMENT (ADRENALINE OR  PLACEBO) - IN A  NUTSHELL 
DETAIL ADRENALINE 
(n=50) 
PLACEBO 
(n=50) 
RELATIVE 
RISK 
P  
VALUE 
NO (%) OF 
REACTION TO 
SERUM 
5 24 0.21 0.00005 
TIMING OF 
ADVERSE 
REACTIONS TO 
SERUM (MIN) 
    
<15 4 19   
15-30 1 5   
>30 0 0   
NO (%) OF 
REACTIONS  
ACCORDING TO 
SEVERITY 
    
MILD 4 12 0.67 .03 
MODERATE 1 8 .125 .01 
SEVERE 0 4 0 .03 
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OBSERVATION 
 
 
 
 
 
 
 
 
 OBSERVATION 
 
SEX  DISTRIBUTION  IN STUDY AND  PLACEBO GROUP 
DETAIL ADRENALINE 
(n-50) 
PLACEBO 
(n-50) 
MALE 32 30 
FEMALE 18 20 
 
STUDY GROUP 
32
18
male
Female
 
PLACEBO GROUP 
30
20
male
female
 
  
 The data shows that there is no significant difference in sex 
distribution  among study and placebo group. 
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 MEAN AGE AMONG MEMBERS IN STUDY AND PLACEBO  GROUP 
 
MALE 
 
DETAIL ADRENALINE PLACEBO 
MEAN (SD ; RANGE) 
AGE (YEARS) 
40.19 
(13.07 ; 19-65) 
41.77 
(11.6; 17-65) 
 
 
40.19 41.77
0
10
20
30
40
50
ADRENALINE PLACEBO
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 FEMALE 
 
 
DETAIL ADRENALINE PLACEBO 
MEAN (SD; RANGE) 
AGE (YEARS) 
32.06 
(8.35 ; 19-45) 
36.45(11.10 ; 14-55) 
 
 
32.06
36.45
0
10
20
30
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 The  mean age of both males  and females  did not grossly  differ 
among study and placebo group  as evidenced by the data above. 
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WEIGHT DISTRIBUTION AMONG MEMBERS IN STUDY AND  
PLACEBO GROUP 
 
MALE 
 
DETAIL ADRENALINE PLACEBO 
(SD ; RANGE) 
WEIGHT (KG) 
58.22 
(4.94 ; 48-66) 
58.17 
(5.04; 50-70) 
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FEMALE 
 
DETAIL ADRENALINE PLACEBO 
(SD ; RANGE) 
WEIGHT (KG) 
45.28 
(5.30 ; 38 - 54) 
47.4 
47.4 (5.36; 28-54) 
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 The data  shows no significant  difference  in the mean weight  
among study and placebo group in both sexes.  
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SPECIES OF  SNAKES 
COMPARISON BETWEEN STUDY AND PLACEBO GROUP 
 
DETAIL ADRENALINE PLACEBO 
UNCERTAIN 22 31 
RUSSELL'S VIPER 18 13 
COBRA 3 3 
KRAIT 7 3 
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 In 22 out of  50 patients  among study group and 31 out  of 50 
patients among placebo  group the  snake could not  be caught  and thus  
remained unidentified.  18  snake  bites in study  group and  13 in placebo  
group were  due to Russell's  viper.  Cobra and Krait  bites were relatively 
rare as evidenced by the data.   
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 SYSTEMIC  ENVENOMATION :  COMPARISON BETWEEN  
STUDY AND PLACEBO GROUP 
 
Coagulopathy 22 30 
Neuromuscular Complications 16 10 
Renal impairment 5 3 
 
More than one feature of envenomation  5 3 
Coagulopathy &  Neuromuscular 0 0 
Coagulopathy & renal 5 3 
Neuromuscular and renal 0 0 
Coagulopathy neuromuscular & renal 0 0 
 
Significant local envenomation   only 6 5 
Local  swelling 26 34 
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  A good proportion of patients - 22 in study group and 30 in placebo 
group developed  coagulopathy.  Neuromuscular complications were seen 
in 16 and  10 patients  in study and placebo groups respectively  where as  
renal impairment  was seen in 5  patients in study group and 3 in  placebo 
group. 
 
 Combinations of  systemic  envenomation  per se was rare.    5 
patients  in  study group and 3 patients in placebo group  developed 
features of both coagulopathy and acute  renal failure. 
 
 A high proportion of patients in both study  and placebo groups 
developed local  swelling.  This was found to be 52%  (26 patients)  and 
68%  (34 patients)  respectively.  6 patients  in study group and 5 in 
placebo group had significant local  envenomation  which was  cellulitis 
extending to more than  half of the  bitten limb.  None of these patients 
had necrosis.   
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 ACUTE  ADVERSE  REACTIONS TO ANTIVENOM SERUM TO 
PATIENTS BITTEN BY  SNAKES,  ACCORDING TO PRE 
TREATMENT  (ADRENALINE OR PLACEBO) 
 
DETAIL ADRENALINE 
(n=50) 
PLACEBO 
(n=50) 
RELATIVE 
RISK 
P 
VALUE 
NO (%)  OF 
REACTION TO  
SERUM 
5 24 0.21 .00005 
 
TABLE - A 
 
ADRENALINE 
 
45
5
REACTION -
NIL
     REACTION  
 
 
PLACEBO 
 
24
26 REACTION
NO REACTION
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PERCENTAGE OF REACTIONS ACCORDING TO SEVERITY 
% OF 
REACTIONS 
ACCORDING 
TO 
SEVERITY 
ADRENALINE 
n=50 
PLACEBO 
(n=50) 
RELATIVE 
RISK 
P 
VALUE 
MILD 4 12 0.67 .03 
MODERATE 1 8 0.125 .01 
SEVERE 0 4 0 .03 
TABLE  - B 
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None of the study patients  died.  Table A   shows the incidence of  acute  
adverse reactions  to antivenom  serum.  There was a highly significant  
reduction of  acute  adverse  events  in the adrenaline group.  Significant  
reductions in  acute  adverse reactions to the serum  were  also  seen in 
adrenaline  group for each category   of mild,  moderate  and  severe  
reaction.  (P value  .03, .01, .03  respectively) See Table B. 
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 TIMING OF ADVERSE REACTIONS TO SERUM (MIN) 
 
TIMING OF ADVERSE 
REACTIONS TO SERUM 
(MIN) 
ADRENALINE PLACEBO 
<15 4 19 
15-30 1 5 
>30 0 0 
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 Of the total 5 patients in study group, who developed reaction, 4 
developed it within 15 minutes and 1 between 15 to 30 minutes.  Of the 
total  24 patients who developed  reaction  in placebo  group 19 
developed  it within 15 minutes while 5 patients  developed it  between  
15 to 30 minutes.  None of the patients, both in study and placebo group 
developed reaction after 30 minutes of starting the antivenin.  
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SIDE EFFECTS OF ADRENALINE 
 
 In none of the patients  who received  adrenaline  or  placebo  had 
blood pressure over  160/100mm Hg nor did any  experience  
neurological  deficit suggestive of a cerebrovascular  accident  during  
monitoring. Two patients who  received  adrenaline and  seven who  
received  placebo  developed   sinus  tachycardia.  No  patient  developed  
any other arrhythmia.  Transient drowsiness  was observed in  patients  in 
the  adrenaline  group and  in the placebo group.  These were  probably  
the effects of  premedication  (all patients had other  features  of  a 
moderate or severe acute  adverse  reaction  to the serum). 
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DISCUSSION 
 
 
 
 
 
 
 
 
 DISCUSSION 
 
There is  no clear  scientific  evidence  or  uniform  policy for the 
use of  premedication to  prevent  acute   adverse  reactions  to  
antivenom  serum.  Among the drugs  used, hydrocortisone and 
antihistamines, although  probably  of  little value, seem to be  the most  
preferred.  Adrenaline  is used  only in a few centres47.  (In  a 
restrospective  analysis of the  use of premedication  before  treatment  
with  antivenom  serum  for snake bite  in  Australia, adrenaline,  steroids 
and  anti histamines used in  different  combinations  were  found to  
reduce adverse reactions  to the serum  from 12.5%  to  3%.  Although   
the data  did not differentiate  between effects of individual drugs,  the 
most effective  premedication in the  combinations  seemed to be  
adrenaline. 
 
 A major  concern regarding  the use of  adrenaline as  
premedication is the  potential  risk of intracerebral  haemorrhage;  a 
result of the combination  of the ability of certain  snake  venoms  to  
cause  coagulopathy and  the risk of  hypertension with the  use of 
adrenaline.  This has  led to a  reluctance  to use adrenaline.    Few studies 
have  analysed the risk of  cerebral  haemorrhage after  use  of  
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 adrenaline.  Of seven cases  of  fatal intracerebral  haemorrhage  after  
snake bite  documented  in Australia,  only three  patients  had  received  
adrenaline as  premedication  making  the evidence  incriminating  
adrenaline as the  cause of  cerebral  haemorrhage  weak 50.  Fears of 
development  of  hypertension  after  low dose  adrenaline  also  seem  
unfounded.  In a study  by  Heilborn et al,  eight  patients  who  received. 
5 mg  adrenaline  subcutaneously   showed  only  transient  and probably  
insignificant  rises in systolic  blood pressure,  while  diastolic blood  
pressure  decreased16. 
 
 This study is a prospective  randomized,  placebo  controlled  trial 
to  investigate  the  efficacy and safety  of   adrenaline  as  prophylaxis  
against  acute  adverse  reactions to antivenom.  Pretreatment  with  a 
small dose  of  subcutaneous  adrenaline  significantly   reduced  the  
incidence  of  acute  adverse   reactions  to  polyvalent   antivenom  
serum.   Adrenaline  is  cheap and easy  to use.  No significant   adverse  
effects  attributable  to adrenaline  was encountered  during the  study;  
there were  no cases of acute  neurological  deficit  suggestive  of  
cerebrovascular  accidents or patients in whom blood pressure  rose 
significantly.  It must be  pointed out,   however  that patients who were  
potentially  at high risk  for use of adrenaline  were   excluded  from  the 
study and  results  regarding  its  safety  should be  viewed  in this  
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 context.  Nevertheless,  the benefits  of this treatment  seem to  outweigh  
potential   risks.  The  use of  low dose   subcutaneous  adrenaline  as a  
prophylactic measure  to  prevent  acute  adverse reactions  to antivenom 
can be  recommended  in  patients  who have no  contraindications for  its 
use. 
 
 Studies by Premawardhena. P et al  (1999)34,  the first  of its kind, 
has given similar results.  Regarding reactions to serum, P value was 
found to be 0.0002  while in our study it is 0.00005.  Both being 
statistically very significant. 
 
 In the Srilankan study, P value for mild,  moderate and severe  
reactions were  found to  be 0.05,   0.04 and 0.04  respectively.  In our 
study it was  .03, .01 and .03  respectively;  all the values being  
statistically  significant; thus proving the benefits of prophylactic  
adrenaline in preventing acute  adverse  effects to ASV. 
 
 Regarding  the timing of the reaction,  in Srilankan  study,  5 out of  
6 in study group and  19 out of 21 in placebo group  developed  reactions 
within 15 minutes of  starting ASV,  while in our  study the  figures were  
4 out of 5 and 19 out of 24 respectively. 
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  In the  Srilankan study,  1 out of 6 in study group  and 2 out of 21 
in the  placebo  group developed  reaction  between 15 to 30  minutes  
while in our study,  1out of  5 in the study  group and 5  out of 24  in the 
placebo  group developed  reactions  in this time  period. 
 
None of the patients in  either the study  or the placebo group in 
both the Srilankan and  our study  developed  reactions to ASV  beyond 
30 minutes  of starting the drip. 
 
In both  the studies,  there was no statistically significant  
difference  among any  variables  between  the  study and placebo group. 
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CONCLUSION 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
1.  Antivenom serum is the only  effective treatment for   
envenomation after  snake bite. 
2. Acute  adverse reactions  to the  serum  are  common and include  
anaphylactic  shock. 
3. Acute  adverse  reactions almost  never  occur  beyond  30 
minutes  of starting ASV drip. 
4.  The Prophylactic use of  1:1000 adrenaline in a dose of  0.25 ml  
given  subcutaneously immediately  before the infusion   of  antivenom  
serum significantly  reduces  the  risk of  acute  adverse  reactions. 
 5.  Significant side effects  attributable to  adrenaline  almost  never 
occur  on giving prophylactic  adrenaline to  prevent adverse  reactions to  
antivenom serum.   
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 PROFORMA 
 
NAME  :   AGE  :  SEX  :  IP NO : 
 
ADDRESS :  
   
OCCUPATION :  WEIGHT : 
 
SPECIES OF SNAKE : UNCERTAIN : 
    VIPER : 
    COBRA  : 
    KRAIT    : 
FIRST  AID BEFORE  ADMISSION :   RECEIVED / NOT  RECEIVED  
MEAN  DELAY IN ADMISSION TO HOSPITAL : 
 
CONTRAINDICATIONS TO STUDY :    
 
AGE  <12 YRS       
AGE>70 YRS       
RECEIVED  ANTISERA     
RECEIVED  ANTISERA IN THE PAST :        
ENVENOMATION 
A/R TO ADRENALINE     
ATOPY 
WHEEZING 
HYPERTENSION 
IHD        
TIA       
STROKE 
UNEXPLAINED FOCAL NEUROLOGICAL SIGNS 
PRIOR TREATMENT OTHER THAN FIRST AID  
A          P 
 SYSTEMIC  ENVENOMATION 
       BT 
COAGULOPATHY :    CT 
NEUROMUSCULAR : 
RENAL  : 
CELLULITIS 
SEVERE  LOCAL  SWELLING : 
ASV REACTION   
MILD       MODERATE   SEVERE 
PRURITIS     EXTENSIVE URTICARIA PULMONARY OEDEMA: 
SKIN RASH    FACIAL OEDEMA  BRONCHOSPASM WITH 
URTICARIA    BRONCHOSPASM  CYANOSIS 
FEVER    WITHOUT CYANOSIS  STRIDOR 
RIGOR      SHOCK 
NAUSEA 
VOMITING 
 
A :  Adrenaline  group 
P  :  Placebo group 
 
  
 
 
 
 
BEFORE  
ASV 
DURING / AFTER 
ASV 
  
  
 
BP :
ECG :
  
 
 
 
PROFORMA AND  
MASTER  CHART 
 MASTER  CHART 
Sl. 
No. Name Age Sex IP No. 
ASV 
Vials DOA 
WT 
Kg 
Species of 
Snake * C CG R NP React Timing Severity 
1.  Paramasivam 25 M 948009 10 06-07-07 60 Uncertain C + - - R <15 Mild 
2.  Arokyadas 43 M 947608 10 06-07-07 58 Russel C + - - R <15 Mod 
3.  Ilayakumar 31 M 948046 10 07-07-07 63 Russel C + + -    
4.  Chellakannu 47 M 948186 10 08-07-07 56 Uncertain C + - - R <15 Severe 
5.  Nagarajan 62 M 948408 10 10-07-07 52 Uncertain C + - -    
6.  Ambika 22 F 948738 10 13-07-07 50 Uncertain - - - +    
7.  Suresh 27 M 948620 10 12-07-07 66 Russel S + + -    
8.  Chinnayyan 40 M 948825 10 14-07-07 56 Cobra - - - +    
9.  Ponni 40 F 948859 10 14-07-07 54 Uncertain C + - -    
10.  Selvaraj 45 M 949472 10 19-07-07 58 Uncertain C - - - R 15-30 Mild 
11.  Sasikumar 25 M 949714 10 21-07-07 65 Uncertain - - - +    
12.  Chinnayya 33 M 950170 10 24-07-07 68 Russel C - - -    
13.  Kalimuthu 45 M 950061 10 24-07-07 54 Russel C - - -    
14.  Mathi 48 M 950390 10 25-07-07 56 Cobra - - - +    
 Sl. 
No. Name Age Sex IP No. 
ASV 
Vials DOA 
WT 
Kg 
Species of 
Snake * C CG R NP React Timing Severity 
15.  Perumal 50 M 950385 10 26-07-07 58 Russel C + - -    
16.  Anthonysamy 25 M 950375 10 26-07-07 70 Uncertain - + - - R <15 Mild 
17.  Anbalagan 57 M 950533 10 27-07-07 58 Russel C + - - R <15 Mild 
18.  Rajasekar 21 M 951087 10 01-08-07 58 Uncertain S + + -    
19.  Sivalingam 40 M 951087 10 01-08-07 60 Uncertain - - - -    
20.  Arulsamy 37 M 951093 10 03-08-07 64 Russel C  + - - R <15 Mild 
21.  Nagaraj 50 M 951302 10 03-08-07 58 Cobra - - - +    
22.  Sakthivel 17 M 951330 10 05-08-07 50 Russel C + - -    
23.  Segamelam 60 M 951583 10 06-08-07 52 Uncertain - - - +    
24.  Thangavelu 60 M 951678 10 06-08-07 58 Russel C + - - R <15 mild 
25.  Murugan 32 M 951689 10 07-08-07 52 Russel C + + -    
26.  Balayya 35 M 951811 10 08-08-07 60 Uncertain - + - -    
27.  Kathalingam 26 M 951928 10 08-08-07 66 Uncertain S + + -    
28.  Divyaraj 37 M 951983 10 09-08-07 64 Uncertain C + - -    
29.  Krishnamoorthy 48 M 952232 10 01-08-07 58 Cobra - - - +    
 Sl. 
No. Name Age Sex IP No. 
ASV 
Vials DOA 
WT 
Kg 
Species of 
Snake * C CG R NP React Timing Severity 
30.  Govindaraj 45 M 952377 10 12-08-07 62 Uncertain C + - -    
31.  Sumathi 35 F 951480 10 04-08-07 51 Russel C - - - R <15 mod 
32.  Nandhini 14 F 952333 10 12-08-07 28 Russel C + - -    
33.  Rengaraj 22 M 942354 10 12-08-07 64 Krait - - - +    
34.  Samuthram 30 M 952761 10 16-08-07 60 Uncertain C - - - R <15 severe 
35.  Rani 24 F 952529 10 14-08-07 46 Russel C + - -    
36.  Vairam 47 F 952550 10 14-08-07 48 Russel C + - -    
37.  Veeramani 38 M 952819 10 16-08-07 62 Uncertain S + - -    
38.  Rajanagam 45 M 952846 10 16-08-07 64 Russel C - - - R <15 mild 
39.  Govindaraj 45 M 953130 10 19-08-07 58 Russel C + - -    
40.  Arjunan 45 M 953140 10 19-08-07 64 Krait - - - + R 15-30 mod 
41.  Lakshmanan 36 M 953277 10 19-08-07 62 Uncertain S + - -    
42.  Sasikala 32 F 953175 10 20-08-07 50 Krait C - - +    
43.  Nabeesabeevi 20 F 953310 10 21-08-07 42 Russel C + - -    
44.  Samiammal 55 F 953610 10 23-08-07 52 Uncertain C - - - R 15-30 mild 
 Sl. 
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45.  Kalaiyanarasan 25 M 953900 10 25-08-07 66 Krait C - - +    
46.  Saroja 45 F 954080 10 26-08-07 54 Uncertain C + - -    
47.  Sumathy 25 F 954045 10 27-08-07 48 Uncertain C - - -    
48.  Malathy 28 F 954192 10 27-08-07 52 Uncertain C - - - R <15 mod 
49.  Kalyani 43 F 954196 10 27-08-07 54 Russel C - - -    
50.  Kulandaiy yamal 55 F 954359 10 29-08-07 52 Uncertain C + - -    
51.  Chandran 60 M 954471 10 30-08-07 60 Uncertain C - - -    
52.  Ramachardran 60 M 954483 10 30-08-07 52 Uncertain C + + -    
53.  Saroja 30 F 954786 10 01-09-07 38 Russel C + - -    
54.  Shanmugam 30 M 955085 10 03-09-07 54 Uncertain - - - + R 15-30 mild 
55.  Karupayyan 50 M 955192 10 04-09-07 50 Uncertain C - - +    
56.  Sundar 38 M 955261 10 04-09-07 56 Uncertain S + - - R <15 mild 
57.  Pusphalatha 29 F 955756 10 04-09-07 38 Uncertain - + - -    
58.  Sandaradevi 45 F 955188 10 04-09-07 42 Uncertain S + - - R <15 mod 
59.  Dhanalakshmi 40 F 955241 10 04-09-07 41 Russel C + - -    
 Sl. 
No. Name Age Sex IP No. 
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60.  Kaliyammal 40 F 955346 10 05-09-07    47 Krait - - - +    
61.  Manoharan 23 M 955117 10 05-09-07 60 Uncertain - - - +    
62.  Muniyatha 45 F 955722 10 08-09-07 48 Uncertain C - - -    
63.  Apoorvam 45 F 955749 10 08-09-07 44 Russel C - - - R 15-30 mild 
64.  Reetamary 28 F 955773 10 09-09-07 45 Russel C + - -    
65.  Susheela 21 F 955950 10 10-09-07 40 Uncertain - - - +    
66.  Indirani 35 F 956041 10 11-09-07 51 Uncertain C + - - R <15 mild 
67.  Sumathy 38 F 956127 10 12.09.07 40 Krait - - - +    
68.  Krishnamoorthy 40 M 955929 10 10.09.07 52 Uncertain C + - - R <15 mod 
69.  Sekar 30 M 955943 10 10.09.07 60 Uncertain - - - +    
70.  Arumainesan 55 M 956347 10 13.09.07 52 Uncertain S + - -    
71.  Rani 40 F 956122 10 12.09.07 48 Uncertain - + - -    
72.  Yamuna 25 F 956264 10 13.09.07 46 Russel C + - - R <15 severe 
73.  Sahayarani 38 F 956258 10 13.09.07 52 Russel C - - -    
74.  Elizabeth 48 F 956247 10 13.09.07 50 Cobra - - - +    
 Sl. 
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75.  Kavitha 19 F 956390 10 14.09.07 40 Krait - + - -    
76.  Veerammal 40 F 956433 10 14.09.07 44 Russel C + - - R <15 mild 
77.  Rajagopal 50 M 956588 10 15.09.07 54 Krait - - - +    
78.  Jayachitra 25 F 957027 10 16.09.07 46 Russel C + - - R 15-30 mild 
79.  Anandan 35 M 957112 10 17.09.07 56 Uncertain C - - -    
80.  Muthukannu 40 F 957144 10 17.09.07 48 Uncertain C - - +    
81.  Kaliyan 65 M 957386 10 18.09.07 48 Krait - - - +    
82.  Vadivel 65 M 957410 10 18.09.07 52 Uncertain C + - - R <15 Mild 
83.  Palanisamy 19 M 957496 10 19.09.07 54 Russel C - - -    
84.  Poomalai 32 M 957552 10 19.09.07 62 Uncertain - - - + R <15 Mod 
85.  Kamaraj 48 M 957537 10 19.09.07 48 Russel C + + - R <15 Mild 
86.  Kumar 45 M 957687 10 20.09.07 54 Uncertain S + - -    
87.  Mala 25 F 957701 10 21.09.07 40 Uncertain S + - -    
88.  Thirugnanam 60 M 957745 10 21.09.07 56 Russel C + - - R <15 Mod 
89.  Kavitha 25 F 957914 10 22.09.07 44 Cobra - - - +    
 Sl. 
No. Name Age Sex IP No. 
ASV 
Vials DOA 
WT 
Kg 
Species of 
Snake * C CG R NP React Timing Severity 
90.  Palani 30 M 957963 10 23.09.07 62 Uncertain C + - -    
91.  Govindaraj 40 M 1958207 10 24.09.07 56 Uncertain C - - -    
92.  Indiragandhi 35 F 958349 10 25.09.07 49 Uncertain C - - - R <15 severe 
93.  Shanmughanathan 30 M 958239 10 25.09.07 60 Krait - - - +    
94.  Sakkararathi 42 M 958367 10 25.09.07 63 Uncertain - + - -    
95.  Chinnaiyyan 40 M 958474 10 26.09.07 59 Uncertain - - - +    
96.  Mudiyappan 53 M 958631 10 27.09.07 52 Uncertain C + - - R <15 mod 
97.  Sarasu 40 F 958495 10 26.09.07 49 Russel S + - -    
98.  Mariyayi 25 F 958781 10 28.09.07 46 Uncertain C + + -    
99.  Ramasamy 52 M 958873 10 29.09.07 54 Uncertain C + - -    
100. Dhanapal 50 M 958940 10 30.09.07 52 Uncertain C - - -    
 
 
 
 
 Sl. No.  : SERIAL NO. 
C  : CELLULITIS 
S  : SEVERE  CELLULITIS EXTENDING  MORE THAN HALF OF THE LIMB 
WT  : WEIGHT IN  KILOGRAMS 
*SPECIES OF  SNAKE    DOCUMENTED  ONLY  IF THE SNAKE  WAS  BROUGHT  BY  THE ATTENDER 
CG  : Coagulopathy 
R  : Renal failure 
NP  : Neuroparalytic manifestations 
React  : Anaphylactic  Reaction 
Timing : in Minutes 
Mod  : Moderate 
 
              Adrenaline 
               Placebo  
